Assessing Equifax (EFX) Valuation After Strong Q1 Results And A Post Earnings Share Price Slide
Equifax EFX | 0.00 |
Equifax (EFX) has packed several developments into recent weeks, from a strong first quarter that beat revenue expectations to new technology partnerships and industry recognition, yet the stock has fallen sharply since the earnings release.
The recent 13.7% slide in the share price after earnings adds to a year-to-date share price return that is down 19.6%, while the 1 year total shareholder return has fallen 35.2%. This points to fading momentum despite upbeat quarterly news and partnerships.
If this kind of mixed sentiment around Equifax has you reassessing your watchlist, it could be a useful moment to scan for other data driven opportunities in 48 AI infrastructure stocks
With Equifax reporting double digit revenue and net income growth alongside new partnerships, yet trading around a 57% intrinsic discount and roughly 30% below analyst targets, the key question is whether this weakness signals an opportunity or if the market is already adjusting for future growth.
Most Popular Narrative: 23.1% Undervalued
Against a last close of $172.13, the most followed narrative pegs Equifax’s fair value near $223.71, framing the recent share price slide as a valuation gap rather than a settled verdict.
Accelerating customer adoption of new multi-data product solutions (e.g., TWN indicator, Single Data Fabric, EFX.AI) and continued high NPI (New Product Introduction) rates are expanding Equifax's value proposition, positioning the company to capture incremental market share and drive sustained organic revenue growth above historical levels.
The core of this narrative is simple. Faster revenue growth, rising margins and a richer product mix are all wired into that fair value. Curious which assumptions really move the model and how they tie back to earnings power over the next few years.
Result: Fair Value of $223.71 (UNDERVALUED)
However, this hinges on Equifax containing elevated litigation and compliance costs, while also managing state-level budget pressures that could keep government-related revenue more volatile.
Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.
Another View: Earnings Multiple Paints a Different Picture
DCF work suggests Equifax trades at a steep 57.1% discount to an estimated fair value of $401.12. However, the P/E of 29.3x is higher than both the peer average of 28.1x and a fair ratio of 26.7x. That tension raises a simple question: is the market underpricing cash flows or overpaying for earnings today?
Next Steps
With sentiment clearly split between risks and rewards, this is a good moment to move quickly and review the data yourself, starting with the 4 key rewards and 2 important warning signs
Looking for more investment ideas?
If Equifax has you thinking harder about where your money works best, do not stop here. Widen your search before the next move passes you by.
- Target reliable income by scanning for companies in 10 dividend fortresses that focus on higher yielding payouts with substance behind them.
- Hunt for quality at a discount by reviewing stocks in 48 high quality undervalued stocks that combine fundamentals with pricing that may not fully reflect them yet.
- Protect your downside by checking out 63 resilient stocks with low risk scores that aim to balance growth potential with steadier risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
